Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Amwill Healthcare IPO
Amwill Health Care Ltd
₹1,26,000 /1200 sharesMinimum Investment
Amwill Healthcare IPO Listing Details
| Listed On | Issue Price | Listing Price | Listing Gains |
|---|---|---|---|
| -- | ₹111.00 | ₹88.85 | -₹22.15 (19.95%) |
Amwill Healthcare IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 5 Feb ‘25 - 7 Feb ‘25 | ₹1,26,000 | 1,200 | ₹105 - ₹111 |
| Issue Size | IPO Doc |
|---|---|
| 59.98Cr | RHP PDF |
Subscription rate
As of 07 Feb'25, 05:00 PM
| Qualified Institutional Buyers | 7.80x |
| Non-Institutional Investor | 5.64x |
| Retail Individual Investor | 4.40x |
| Total | 5.29x |
About Amwill Healthcare
Founded in
2017
Managing director
Mr. Anand Gandhi and Mr. Tarun Gandhi
Parent organisation
Amwill Health Care Ltd
Strengths & Financials of Amwill Healthcare
Strengths
Risks
The company offers a range of products addressing various dermatological issues, including hair care, skin care, and lip care. Its portfolio includes solutions for acne, ageing, fungal infections, allergies, excessive perspiration, skin lightening, specialised hair care, antioxidants, scar treatment, peri-orbital hyperpigmentation, vitiligo, and steroid and keratolytic treatments.
To maintain high-quality standards, the company claims to conduct thorough testing of its formulations through contract manufacturers. This ensures the final product meets the required molecular composition, texture, fragrance, and overall effectiveness. Additionally, prototypes are reviewed by dermatologists to verify their efficacy before launch.
The company has seen a consistent increase in revenue from operations. Revenue from operations increased from Rs 18.00 crore in FY22 to Rs 27.61 crore in FY23 to Rs 30.17 crore in FY24.
The company relies entirely on Amderma Healthcare LLP, a promoter group entity, for storing, delivering, and distributing its products. This entity accounted for Rs 35.44 crore (99.02%) of revenue in the nine months ending December 31, 2023, and Rs 29.63 crore (98.24%), Rs 24.89 crore (90.15%), and Rs 16.41 crore (91.18%) in FY23, FY22, and FY21, respectively. Any failure to meet contractual obligations or operational disruptions in this partnership could negatively impact the business performance and revenue of the company.
The company depends on third-party contract manufacturers for production. Any decline in product quality, delays in delivery, or an increase in manufacturing costs could disrupt operations and affect overall performance.
A major portion of revenue comes from a limited number of products. The top 10 products contributed Rs 10.92 crore (30.51%) in the nine months ending December 31, 2023, and Rs 9.16 crore (30.36%), Rs 7.45 crore (27.00%), and Rs 4.92 crore (27.32%) in FY23, FY22, and FY21, respectively, to the revenue from operations. Any decline in the sales, pricing, or market demand for these products could adversely affect the company’s operations and finances.
Business operations are concentrated in Karnataka, Andhra Pradesh, and Telangana. Any adverse developments in these regions could negatively affect overall operations and financial performance.
The company reported a loss of Rs 1 crore in FY21. Any future losses could further strain operations and financial health.
Amwill Healthcare Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Amwill Healthcare IPO
| Apply as | Price band | Apply Range |
|---|---|---|
| Regular | ₹105 - 111 | ₹2 - 5 Lakh |
| High Networth Individual | ₹105 - 111 | ₹2 - 5 Lakh |
For Amwill Healthcare IPO, eligible investors can apply as Regular.